{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"3.45","upperLimit":"9.76","value":"5.78"},{"groupId":"OG001","lowerLimit":"4.14","upperLimit":"16.66","value":"8.77"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"67"},{"groupId":"OG001","value":"39"}],"units":"Participants"}],"title":"TMB: <7"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"6.41","upperLimit":"16.95","value":"11.37"},{"groupId":"OG001","lowerLimit":"6.28","upperLimit":"12.29","value":"7.16"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"43"},{"groupId":"OG001","value":"21"}],"units":"Participants"}],"title":"TMB: ≥ 7"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"4.96","upperLimit":"11.27","value":"7.52"},{"groupId":"OG001","lowerLimit":"4.90","upperLimit":"13.04","value":"8.31"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"91"},{"groupId":"OG001","value":"49"}],"units":"Participants"}],"title":"TMB: < 10"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"2.50","upperLimit":"41.33","value":"6.51"},{"groupId":"OG001","lowerLimit":"1.35","upperLimit":"17.51","value":"9.26"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"19"},{"groupId":"OG001","value":"11"}],"units":"Participants"}],"title":"TMB: ≥10"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"9.53","upperLimit":"17318","value":"13.86"},{"groupId":"OG001","lowerLimit":"7.56","upperLimit":"23.46","value":"20.01"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"49"},{"groupId":"OG001","value":"22"}],"units":"Participants"}],"title":"Not Reported"}],"denoms":[{"counts":[{"groupId":"OG000","value":"159"},{"groupId":"OG001","value":"82"}],"units":"Participants"}],"description":"Overall survival was defined as the time from randomization to the date of death from any cause. Participants were censored at the date they were last known to be alive and at the date of randomization if they were randomized but had no follow-up.\n\nTumor Mutational Burden (TMB) refers to the number of nonsynonymous somatic mutations that exist within a tumor's genome as measured by the Foundation One CDx panel at Foundation Medicine. The analysis was done on subjects with baseline tumor mutation burden by a cutoff of 7 mutations/megabase (mut/Mb) and 10 mut/Mb","dispersionType":"95% Confidence Interval","groups":[{"description":"Participants with histologically confirmed Squamous Cell Carcinoma of the Head and Neck (SCCHN) that has recurred during or less than 6 months after completion of previous platinum-based chemotherapy.\n\nTreated with Nivolumab 3 mg/kg Q2W + Ipilimumab 1 mg/kg Q6W","id":"OG000","title":"Treatment A - Platinum Refractory Subgroup"},{"description":"Participants with histologically confirmed Squamous Cell Carcinoma of the Head and Neck (SCCHN) that has recurred during or less than 6 months after completion of previous platinum-based chemotherapy.\n\nTreated with Nivolumab 3 mg/kg Q2W + Ipilimumab-Placebo Q6W","id":"OG001","title":"Treatment B - Platinum Refractory Subgroup"}],"paramType":"MEDIAN","populationDescription":"All Randomized Participants - Platinum Refractory Subgroup","reportingStatus":"POSTED","timeFrame":"From randomization to death. Approximately 63 Months","title":"Overall Survival (OS) - Platinum Refractory Subgroup Based on Tumor Mutation Burden (TMB) Status","type":"SECONDARY","unitOfMeasure":"Months"}